# DYNAVAX TECHNOLOGIES CORP — merger [completed]
Source: SEC API (secapi.ai) · situation sit_21c5a8ce9126bf29653c · retrieved 2026-08-11T16:16:03.803Z

## Overview
Dynavax Technologies Corporation is a pharmaceutical company developing vaccines and immunotherapies.

Samba Merger Sub, Inc., a wholly owned subsidiary of Sanofi, launched a tender offer to purchase all outstanding shares of Dynavax Technologies Corporation for $15.50 per share in cash. The offer expired on February 9, 2026, with 84,680,752 shares (approximately 73.92% of outstanding shares) validly tendered. Purchaser has irrevocably accepted all tendered shares for payment. Pursuant to Delaware General Corporation Law Section 251(h), Sanofi and Purchaser intend to complete the acquisition through a merger without a stockholders' meeting, with each remaining share (excluding treasury shares, shares held by Parent or its subsidiaries, tendered shares, and appraisal-demanding shares) to be converted into the right to receive $15.50 per share.

## Terms
- Counterparty: Sanofi · Consideration: cash · Stake: 73.92% · Price/share: $15.5

## Key dates
- Expiry 2026-02-09

## Timeline
- 2026-01-12 · SC 14D9 (0001193125-26-009777): SC 14D9 - DYNAVAX TECHNOLOGIES CORP — *Dynavax Technologies Corporation is a biopharmaceutical company that develops and commercializes vaccines, including HEPLISAV-B (hepatitis B vaccine) as its primary marketed product, and is advancing a pipeline of vaccine candidates including shingles, Lyme disease, and oral COVID vaccines.* Sanofi, through its subsidiary Samba Merger Sub, Inc., launched a tender offer to acquire all outstanding shares of Dynavax Technologies Corporation for $15.50 per share in cash. The offer, which commenced on January 12, 2026, is scheduled to expire on February 9, 2026, unless extended. The transaction is governed by an Agreement and Plan of Merger dated December 23, 2025. The offer is conditioned on, among other things, the tender of a majority of outstanding shares and satisfaction of customary closing conditions including regulatory approvals. Upon consummation, Dynavax will cease to be publicly traded and will become a wholly owned subsidiary of Sanofi.
  https://www.sec.gov/Archives/edgar/data/1029142/0001193125-26-009777.txt
- 2026-02-10 · SC 14D9/A (0001193125-26-043626): SC 14D9/A - DYNAVAX TECHNOLOGIES CORP — *Dynavax Technologies Corporation is a pharmaceutical company developing vaccines and immunotherapies.* Samba Merger Sub, Inc., a wholly owned subsidiary of Sanofi, launched a tender offer to purchase all outstanding shares of Dynavax Technologies Corporation for $15.50 per share in cash. The offer expired on February 9, 2026, with 84,680,752 shares (approximately 73.92% of outstanding shares) validly tendered. Purchaser has irrevocably accepted all tendered shares for payment. Pursuant to Delaware General Corporation Law Section 251(h), Sanofi and Purchaser intend to complete the acquisition through a merger without a stockholders' meeting, with each remaining share (excluding treasury shares, shares held by Parent or its subsidiaries, tendered shares, and appraisal-demanding shares) to be converted into the right to receive $15.50 per share.
  https://www.sec.gov/Archives/edgar/data/1029142/0001193125-26-043626.txt

## Citations
- 0001193125-26-009777 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526009777
- 0001193125-26-043626 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526043626